Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Coeptis Therapeutics Holdings Inc (COEPW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: COEPW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -89.12% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.59 | 52 Weeks Range 0.00 - 0.05 | Updated Date 02/25/2025 |
52 Weeks Range 0.00 - 0.05 | Updated Date 02/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -245.55% | Return on Equity (TTM) -1449.7% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 12704886 |
Shares Outstanding - | Shares Floating 12704886 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Coeptis Therapeutics Holdings Inc
Company Overview
History and Background
Coeptis Therapeutics Holdings, Inc. was founded to develop and commercialize innovative technologies addressing unmet medical needs. They focus on cancer and other serious conditions. Details on founding year and precise milestones are currently not available in accessible public sources but the company has undergone significant restructuring and strategic shifts.
Core Business Areas
- Drug Development: Focused on developing and commercializing innovative drug candidates for oncology and other diseases.
- Cell Therapy: Investigating and developing cell therapy approaches for treating various conditions, specifically focusing on stem cell therapies and immunotherapies
- Exosome Technology: Exploring exosomes, nano-sized vesicles released by cells, for potential diagnostic and therapeutic applications.
Leadership and Structure
Details of exact leadership structure and organizational hierarchy are currently not fully available in easily accessed public sources. However, the company has a CEO and a board of directors, overseeing the strategic direction and operations of the company.
Top Products and Market Share
Key Offerings
- CD-38 CAR-T: CAR-T therapy targeting CD38 for multiple myeloma. Market share is nascent as it is in clinical trials. Competitors include JNJ (JNJ) with Darzalex and other CAR-T therapies from major pharmaceutical companies.
- Consensus platform: The Consensus platform is a cancer diagnostic tool used to provide comprehensive analysis of patientsu2019 tumors. Market Share is nascent as it is in clinical trials. Competitors include multiple companies that offer diagnostic services for cancer.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. Key trends include personalized medicine, gene therapy, and immunotherapy.
Positioning
Coeptis Therapeutics Holdings Inc is a smaller player in the biopharmaceutical industry, focusing on innovative but high-risk drug development. Their competitive advantage lies in novel therapeutic approaches and strategic partnerships.
Total Addressable Market (TAM)
The TAM for cancer therapeutics is estimated to be hundreds of billions of dollars. Coeptis Therapeutics Holdings Inc's position is highly speculative, depending on the success of their clinical trials and commercialization efforts.
Upturn SWOT Analysis
Strengths
- Innovative therapeutic approaches
- Strategic partnerships
- Potential for breakthrough therapies
Weaknesses
- Limited financial resources
- High risk associated with drug development
- Dependence on clinical trial outcomes
Opportunities
- Expanding market for cancer therapeutics
- Potential for breakthrough therapies
- Increasing interest in personalized medicine
Threats
- Regulatory hurdles
- Competition from larger pharmaceutical companies
- Clinical trial failures
Competitors and Market Share
Key Competitors
- JNJ
- BMY
- MRK
- GILD
Competitive Landscape
Coeptis Therapeutics Holdings Inc faces significant competition from larger, well-established pharmaceutical companies with greater resources and established product portfolios. Their advantage lies in their innovative therapeutic approaches, but they must overcome significant challenges in clinical development and commercialization.
Major Acquisitions
None Listed
- Year: 0
- Acquisition Price (USD millions): 0
- Strategic Rationale: N/A
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been volatile and dependent on acquisitions and strategic shifts.
Future Projections: Future growth projections depend on clinical trial success and commercialization efforts. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include strategic collaborations and clinical trial advancements.
Summary
Coeptis Therapeutics Holdings Inc is a speculative biotechnology company with potential for high growth, but also significant risk. Their innovative therapeutic approaches offer promise, but their limited financial resources and reliance on clinical trial success pose significant challenges. Investors should carefully consider the company's risk profile before investing.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports (where available)
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. The data may not be exhaustive and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Coeptis Therapeutics Holdings Inc
Exchange NASDAQ | Headquaters Wexford, PA, United States | ||
IPO Launch date 2020-12-17 | Co-Founder, Chairman, CEO & Pres Mr. David Mehalick | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://coeptispharma.com |
Full time employees 4 | Website https://coeptispharma.com | ||
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.